RecruitingOBSERVATIONAL

Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis

This study is about understanding how a medicine called risankizumab changes the quality of life for adults who have moderate to severe plaque psoriasis. Psoriasis is a long-lasting skin condition that causes thick, scaly patches. Risankizumab is already approved for treating psoriasis. This study will follow about 700 people worldwide who have been prescribed risankizumab by their doctors as part of their normal care, over two and a half years. The main goal is to see how this treatment impacts their daily lives. Participants will attend their regular appointments, and the study aims not to add extra tasks for them.

At a glance

Status

Recruiting

Sponsor

AbbVie

Enrolment target

700

Start

09 Sep 2025

Estimated completion

01 Mar 2028

Plaque Psoriasis

What is this study about?

Imagine you have a skin condition called psoriasis, which causes red, scaly patches that can be itchy and uncomfortable. This condition can affect how you feel day-to-day and your overall quality of life. This study wants to understand exactly how a specific medicine, called risankizumab, helps people with moderate to severe plaque psoriasis feel better and live their lives more fully.

Risankizumab is a treatment that doctors already prescribe for psoriasis. This study isn't testing whether the medicine works – we already know it does. Instead, it's looking at how it performs in everyday situations, outside of a strict research setting. About 700 adults around the world who are already taking risankizumab for their psoriasis will be part of this study. They will continue to receive their treatment exactly as their doctor prescribes.

By carefully observing these patients over a period of up to two and a half years, researchers hope to gather valuable information about the real-world impact of risankizumab. This will help doctors and patients better understand the benefits of this treatment on people’s daily lives when managing their psoriasis.

Key takeaways

This study looks at how risankizumab affects the quality of life for adults with psoriasis.
It's for people already receiving risankizumab from their doctor.
You'll get your standard treatment; the study won't change it.
Participation lasts up to two and a half years, following your normal clinic visits.
The study aims to add no extra burden to your usual care.
Your involvement helps improve understanding of psoriasis treatment in real-world settings.

Who may be eligible?

To join this study, you must be an adult with moderate to severe plaque psoriasis. This is based on your doctor's diagnosis, whether or not you also have joint problems related to psoriasis.

You also need to be someone whose doctor has decided to treat you with risankizumab, following the recommended guidelines for this medicine. Importantly, your doctor's decision to prescribe risankizumab must have happened before you even considered joining this study; it shouldn't be because of the study itself.

You cannot join if you currently have or have recently been treated (in the last month) for a sleep disorder. You also can't take part if you are currently involved in another clinical trial or observational study, or if you are receiving other specific types of biologic treatments or small molecule medicines for any reason.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you an adult (18 years or older)?
Do you have moderate to severe plaque psoriasis, diagnosed by your doctor?
Has your doctor already prescribed risankizumab for you, separate from this study?
Are you currently not in another clinical trial or observational study?
Are you not currently receiving specific other biologic or small molecule medicines for any condition?
Have you not been treated for a sleep disorder in the last 30 days?

Answer every question to see your result.

What does participation involve?

If you join this study, you will continue to receive your risankizumab treatment exactly as your doctor has prescribed it, just like you would normally. You will attend your regular doctor's appointments at a hospital or clinic, as part of your usual care, for up to two and a half years. The study team aims for you to have no extra visits or tasks beyond what you already do for your psoriasis treatment. The main thing is that your experience will be observed and recorded over this time.

Potential risks and benefits

The main benefit of joining this study is that you would be contributing to a better understanding of how risankizumab helps people with psoriasis in their daily lives, which could benefit others in the future. As you would be receiving your usual treatment and attending your normal appointments, there are no expected additional risks. You are free to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (73)

Rejuvenation Dermatology - Edmonton Downtown /ID# 276688
Verified postcode
Edmonton, Canada· Recruiting
Winnipeg Clinic /ID# 276751
Verified postcode
Winnipeg, Canada· Recruiting
Wiseman Dermatology Research /ID# 276847
Verified postcode
Winnipeg, Canada· Recruiting
Cca Medical Research /ID# 276944
Verified postcode
Ajax, Canada· Recruiting
Quinte dermatology /ID# 277497
Verified postcode
Belleville, Canada· Recruiting
Dermatrials Research /ID# 276714
Verified postcode
Hamilton, Canada· Completed
Lovegrove Dermatology /ID# 276797
Verified postcode
London, Canada· Recruiting
Lynderm Research Inc /ID# 276755
Verified postcode
Markham, Canada· Recruiting
Rejuvenation Dermatology Clinic Oakville /ID# 277492
Verified postcode
Oakville, Canada· Recruiting
JRB Research inc. /ID# 277730
Verified postcode
Ottawa, Canada· Recruiting
Factor Dermatology /ID# 278610
Verified postcode
Ottawa, Canada· Recruiting
SKiN Centre for Dermatology /ID# 277594
Verified postcode
Peterborough, Canada· Recruiting

Common questions

What is plaque psoriasis?

It's a common, long-lasting skin condition where skin cells build up, forming thick, red patches covered with silvery scales.

What is risankizumab?

It's a medicine approved for treating plaque psoriasis that helps reduce inflammation and clear up skin patches.

Will I get risankizumab if I join this study?

Only if your doctor has already decided to prescribe it to you as part of your usual treatment, and you are already receiving it.

Will joining this study change my psoriasis treatment?

No, you will receive your treatment exactly as your doctor prescribes it, following your usual care plan.

What does 'quality of life' mean in this study?

It refers to how your psoriasis and its treatment affect your overall well-being, daily activities, and how you feel about your life.

How to find out more

Julieta Gonzalez Blanco

julieta.gonzalezblanco@abbvie.com 844-663-3742 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.